

Drug	Schedule
Noroxymorphone (9668) .....	II
Racemethorphan (9732) .....	II
Alfentanil (9737) .....	II
Sufentanil (9740) .....	II
Fentanyl (9801) .....	II

The firm plans to manufacture small quantities of the listed controlled substances to make deuterated and non-deuterated drug reference standards which will be distributed to analytical and forensic laboratories for drug testing programs.

No comments or objections have been received.

DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. This investigation included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.

Dated: April 11, 2002.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 02-10300 Filed 4-25-02; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 14, 2001, Irix Pharmaceuticals, Inc., 101 Technology Place Florence, South Carolina 29501, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of methylphenidate

(1724), a basic class of controlled substance listed in Schedule II.

The firm plans to manufacture methylphenidate for sale to their customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA **Federal Register** Representative (CCR), and must be filed no later than June 25, 2002.

Dated: April 11, 2002.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 02-10306 Filed 4-25-02; 8:45 am]

**BILLING CODE 4410-09-M**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on December 3, 2001, Isotec, Inc., 3858 Benner Road, Miamisburg, Ohio 45342, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Aminorex (1585) .....	I
Methaqualone (2565) .....	I
Lysergic acid diethylamide (7315) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
2, 5-Dimethoxyamphetamine (7396) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
3,4-Methyl-enedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methyl-enedioxymethamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I

Drug	Schedule
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
Dihydromorphine (9145) .....	I
Normorphine (9313) .....	I
Acetylmethadol (9601) .....	I
Alphacetylmethadol Except Levo-Alphacetylmethadol (9603) .....	I
Normethadone (9635) .....	I
3-Methylfentanyl (9813) .....	I
Amphetamine (1100) .....	II
Methamphetamine (1105) .....	II
Methylphenidate (1724) .....	II
Amobarbital (2125) .....	II
Pentobarbital (2270) .....	II
Secobarbital (2315) .....	II
1-Phenylcyclohexylamine (7460) .....	II
Phencyclidine (7471) .....	II
Phenylacetone (8501) .....	II
1-Piperidinocyclohexanecarbonitrile (8603) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Benzoyllecgonine (9180) .....	II
Ethylmorphine (9190) .....	II
Hydrocodone (9193) .....	II
Isomethadone (9226) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Methadone intermediate (9254) .....	II
Dextropropoxyphene, bulk (non-dosage forms) (9273) .....	II
Morphine (9300) .....	II
Thebaine (9333) .....	II
Levo-Alphacetylmethadol (9648) .....	II
Oxymorphone (9652) .....	II
Fentanyl (9801) .....	II

The firm plans to manufacture small quantities of the listed controlled substances to produce standards for analytical laboratories.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA **Federal Register** Representative (CCR), and must be filed no later than June 25, 2002.

Dated: April 11, 2002.

**Laura M. Nagel,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 02-10305 Filed 4-25-02; 8:45 am]

**BILLING CODE 4410-09-M**